Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes & metabolism Pub Date : 2024-09-28 DOI:10.1016/j.diabet.2024.101581
Bin Hong , Hyesung Lee , Ahhyung Choi , Woo Jung Kim , Young Min Cho , Dong Keon Yon , Ju-Young Shin
{"title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study","authors":"Bin Hong ,&nbsp;Hyesung Lee ,&nbsp;Ahhyung Choi ,&nbsp;Woo Jung Kim ,&nbsp;Young Min Cho ,&nbsp;Dong Keon Yon ,&nbsp;Ju-Young Shin","doi":"10.1016/j.diabet.2024.101581","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate whether the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors which have shown potential neuroprotective effects, is associated with lower risk of dementia in patients with type 2 diabetes (T2D) and comorbid mental disorders, who are considerably more susceptible to dementia.</div></div><div><h3>Methods</h3><div>Using the nationwide healthcare data of South Korea between 2010 and 2022, we conducted a retrospective cohort study among patients with T2D and comorbid mental disorders initiating SGLT2 inhibitors versus active comparator (Dipeptidyl Peptidase IV (DPP4) inhibitors). Hazard ratios (HRs) and rate differences (RDs) per 1000 person-years of incident dementia were estimated after weighting by propensity score fine stratification method.</div></div><div><h3>Results</h3><div>Over a 4.8-year median follow-up, SGLT2 inhibitors were associated with a 12 % lower risk of dementia compared with DPP4 inhibitors (11.31 vs. 12.86 events per 1000 person years; HR 0.88, 95 % CI 0.84 to 0.92; RD -1.55, -2.13 to -0.97). The results were consistent when stratified by age, sex, individual component, severe mental disorders, presence of insulin, history of cardiovascular disease, or history of hypertension.</div></div><div><h3>Conclusions</h3><div>SGLT2 inhibitors versus DPP4 inhibitors were associated with a lower risk of incident dementia in patients with T2D and comorbid mental disorders. Further randomized controlled trials are required to confirm our findings.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 6","pages":"Article 101581"},"PeriodicalIF":4.6000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363624000739","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim

To evaluate whether the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors which have shown potential neuroprotective effects, is associated with lower risk of dementia in patients with type 2 diabetes (T2D) and comorbid mental disorders, who are considerably more susceptible to dementia.

Methods

Using the nationwide healthcare data of South Korea between 2010 and 2022, we conducted a retrospective cohort study among patients with T2D and comorbid mental disorders initiating SGLT2 inhibitors versus active comparator (Dipeptidyl Peptidase IV (DPP4) inhibitors). Hazard ratios (HRs) and rate differences (RDs) per 1000 person-years of incident dementia were estimated after weighting by propensity score fine stratification method.

Results

Over a 4.8-year median follow-up, SGLT2 inhibitors were associated with a 12 % lower risk of dementia compared with DPP4 inhibitors (11.31 vs. 12.86 events per 1000 person years; HR 0.88, 95 % CI 0.84 to 0.92; RD -1.55, -2.13 to -0.97). The results were consistent when stratified by age, sex, individual component, severe mental disorders, presence of insulin, history of cardiovascular disease, or history of hypertension.

Conclusions

SGLT2 inhibitors versus DPP4 inhibitors were associated with a lower risk of incident dementia in patients with T2D and comorbid mental disorders. Further randomized controlled trials are required to confirm our findings.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
葡萄糖钠转运体 2 抑制剂与二肽基肽酶 IV 抑制剂以及 2 型糖尿病合并精神障碍患者的痴呆风险:基于人群的队列研究
目的:评估具有潜在神经保护作用的钠-葡萄糖共转运体-2(SGLT2)抑制剂的使用是否与2型糖尿病(T2D)患者痴呆风险的降低有关:我们利用 2010 年至 2022 年期间韩国全国范围内的医疗保健数据,对开始服用 SGLT2 抑制剂和活性比较药(二肽基肽酶 IV (DPP4) 抑制剂)的 T2D 和合并精神障碍患者进行了一项回顾性队列研究。通过倾向评分精细分层法进行加权后,估算了每千人年痴呆症发病率的危险比(HRs)和比率差异(RDs):在4.8年的中位随访期间,与DPP4抑制剂相比,SGLT2抑制剂的痴呆风险降低了12%(11.31 vs. 12.86次/1000人年;HR 0.88,95% CI 0.84 to 0.92;RD -1.55, -2.13 to -0.97)。按年龄、性别、个体成分、严重精神障碍、是否使用胰岛素、心血管疾病史或高血压史进行分层后,结果一致:SGLT2抑制剂与DPP4抑制剂相比,可降低合并精神障碍的T2D患者发生痴呆症的风险。需要进一步的随机对照试验来证实我们的研究结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes & metabolism
Diabetes & metabolism 医学-内分泌学与代谢
CiteScore
12.00
自引率
4.20%
发文量
86
审稿时长
13 days
期刊介绍: A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.
期刊最新文献
Medial arterial calcification of the lower limbs in diabetes: Time for awareness? A short narrative review Association of SGLT2 inhibitors with incident cancer Non-dioxin-like polychlorinated biphenyls (NDL-PCBs) dietary exposure is associated with an increased risk of type 2 diabetes in the European prospective investigation into cancer and nutrition (EPIC) cohort Periodontitis adversely affects lipoprotein subfractions – results from the cohort study SHIP-TREND Perirenal fat and chronic kidney disease in type 2 diabetes: The mediation role of afferent arteriolar resistance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1